natgillin/translations-raw huggingface dataset:
Ethylone is monitored by the European Monitoring Centre for Drugs and Drug Addiction as a new psychoactive substance under the terms of Decision 2005/387/JHA.
Etilon spremlja Evropski center za spremljanje drog in zasvojenosti z drogami kot novo psihoaktivno snov pod pogoji Sklepa 2005/387/PNZ.
Ethylone has been detected in 19 Member States.
Etilon je bil odkrit v 19 državah članicah.
Therefore, the Member States should take the position to add ethylone to Schedule II of the Convention on Psychotropic Substances.
Zato bi morale države članice zavzeti stališče, da se etilon doda v Tabelo II Konvencije o psihotropnih substancah.
According to the Expert Committee, the degree of risk to public health and society associated with the abuse of pentedrone or α-methylaminovalerophenone (2-(methylamino)-1-phenylpentan-1-one), is substantial.
Glede na oceno strokovnega odbora je stopnja tveganja za javno zdravje in družbo, povezana z zlorabo pentedrona ali α-metilaminovalerofenona (2-(metilamino)-1-fenilpentan-1-on), precejšnja.
Pentedrone has no recorded therapeutic use.
Evidenc o terapevtski uporabi pentedrona ni.
The Expert Committee considers that there is sufficient evidence that pentedrone is being or is likely to be abused, and therefore constitutes a public health and social problem that warrants placing the substance under international control.
Pentedron spremlja Evropski center za spremljanje drog in zasvojenosti z drogami kot novo psihoaktivno snov pod pogoji Sklepa 2005/387/PNZ.
Thus, the WHO recommends that pentedrone be placed in Schedule II under the Convention on Psychotropic Substances.
Pentedron je bil odkrit v 18 državah članicah.
Pentedrone is monitored by the European Monitoring Centre for Drugs and Drug Addiction as a new psychoactive substance under the terms of Decision 2005/387/JHA.
Povezan je z manjšim številom resnih neželenih dogodkov, tudi s smrtmi.
Pentedrone has been detected in 18 Member States.
Zato bi morale države članice zavzeti stališče, da se pentedron doda v Tabelo II Konvencije o psihotropnih substancah.
It has been associated with a small number of serious adverse events, including deaths.
Glede na oceno strokovnega odbora je stopnja tveganja za javno zdravje in družbo, povezana z zlorabo etilfenidata ali EPH (etil fenil(piperidin-2-il)acetat), precejšnja.
Therefore, the Member States should take the position to add pentedrone to Schedule II of the Convention on Psychotropic Substances.
Evidenc o terapevtski uporabi etilfenidata ni.
According to the Expert Committee, the degree of risk to public health and society associated with the abuse of ethylphenidate or EPH (ethyl phenyl(piperidin-2-yl)acetate) is substantial.
Strokovni odbor ugotavlja, da je mogoče etilfenidat podobno zlorabiti in da lahko ima podobne škodljive učinke kot snovi iz Tabele II Konvencije o psihotropnih substancah.
Ethylphenidate has no recorded therapeutic use.
Ker po mnenju strokovnega odbora o zlorabi ali verjetnosti zlorabe etilfenidata obstaja dovolj dokazov in to zato predstavlja problem javnega zdravja in družbeni problem, je uvedba mednarodnega nadzora nad to snovjo upravičena.
The Expert Committee recognises that ethylphenidate has similar abuse potential to and similar ill-effects to those of substances in Schedule II of the Convention on Psychotropic Substances.
Zato SZO priporoča, da se etilfenidat uvrsti v Tabelo II Konvencije o psihotropnih substancah.
The Expert Committee considers that there is sufficient evidence that ethylphenidate is being or is likely to be abused, and therefore constitutes a public health and social problem that warrants placing the substance under international control.
Etilfenidat spremlja Evropski center za spremljanje drog in zasvojenosti z drogami kot novo psihoaktivno snov pod pogoji Sklepa 2005/387/PNZ.
Thus, the WHO recommends that ethylphenidate be placed in Schedule II under the Convention on Psychotropic Substances.
Etilfenidat je bil odkrit v 13 državah članicah.
Ethylphenidate is monitored by the European Monitoring Centre for Drugs and Drug Addiction as a new psychoactive substance under the terms of Decision 2005/387/JHA.
Povezan je z resnimi neželenimi dogodki, tudi z okužbami mehkega tkiva in smrtnimi primeri.
Ethylphenidate has been detected in 13 Member States.
V okviru sistema zgodnjega opozarjanja na nevarnost je bilo objavljeno opozorilo o nevarnosti, ki jo okužbe mehkega tkiva, povezane z vbrizgavanjem, pomenijo za javno zdravje.
It has been associated with serious adverse events, including soft tissue infections and deaths.
Zato bi morale države članice zavzeti stališče, da se etilfenidat doda v Tabelo II Konvencije o psihotropnih substancah.
Soft tissue infections related to injection have been the subject of a public-health-related alert issued to the Union Early Warning System.
Glede na oceno strokovnega odbora je stopnja tveganja za javno zdravje in družbo, povezana z zlorabo MPA ali metiopropamina (N-metil-1-(tiofen-2-il)propan-2-amin), precejšnja.
Therefore, the Member States should take the position to add ethylphenidate to Schedule II of the Convention on Psychotropic Substances.
Evidenc o terapevtski uporabi MPA ni.
According to the Expert Committee, the degree of risk to public health and society associated with the abuse of MPA or methiopropamine (N-methyl-1-(thiophen-2-yl)propan-2-amine) is substantial.
Strokovni odbor ugotavlja, da je MPA mogoče podobno zlorabiti in da lahko ima podobne škodljive učinke kot snovi iz Tabele II Konvencije o psihotropnih substancah.
MPA has no recorded therapeutic use.
Ker po mnenju strokovnega odbora o zlorabi ali verjetnosti zlorabe MPA obstaja dovolj dokazov in zato predstavlja problem javnega zdravja in družbeni problem, je uvedba mednarodnega nadzora nad to snovjo upravičena.
The Expert Committee recognises that MPA has similar abuse potential to and similar ill-effects to those of substances in Schedule II of the Convention on Psychotropic Substances.
Zato SZO priporoča, da se metiopropamin uvrsti v Tabelo II Konvencije o psihotropnih substancah.
The Expert Committee considers that there is sufficient evidence that MPA is being or is likely to be abused, and therefore constitutes a public health and social problem that warrants placing the substance under international control.
Metiopropamin spremlja Evropski center za spremljanje drog in zasvojenosti z drogami kot novo psihoaktivno snov pod pogoji Sklepa 2005/387/PNZ.
Thus the WHO recommends that methiopropamine be placed in Schedule II under the Convention on Psychotropic Substances.
MPA je bil odkrit v 17 državah članicah.
MPA is monitored by the European Monitoring Centre for Drugs and Drug Addiction as a new psychoactive substance under the terms of Decision 2005/387/JHA.
Povezan je z resnimi neželenimi dogodki, tudi s smrtmi.
MPA has been detected in 17 Member States.
Zato bi morale države članice zavzeti stališče, da se metiopropamin doda v Tabelo II Konvencije o psihotropnih substancah.
It has been associated with serious adverse events, including deaths.
Glede na oceno strokovnega odbora je stopnja tveganja za javno zdravje in družbo, povezana z zlorabo MDMB-CHMICA (metil N-[1-(cikloheksilmetil)-1H-indol-3-il]karbonil-3-metil-L-valinat), precejšnja.
Therefore, the Member States should take the position to add methiopropamine to Schedule II of the Convention on Psychotropic Substances.
Evidenc o terapevtski uporabi MDMB-CHMICA ni.
According to the Expert Committee, the degree of risk to public health and society associated with the abuse of MDMB-CHMICA (methyl N-[1-(cyclohexylmethyl)-1H-indol-3-yl]carbonyl-3-methyl-L-valinate) is substantial.
Strokovni odbor ugotavlja, da se MDMB-CHMICA podobno zlorablja in ima podobne škodljive učinke kot snovi iz Tabele II Konvencije o psihotropnih substancah.
MDBD-CHMICA has no recorded therapeutic use.
Ker po mnenju strokovnega odbora o zlorabi ali verjetnosti zlorabe MDMB-CHMICA obstaja dovolj dokazov in zato predstavlja problem javnega zdravja in družbeni problem, je uvedba mednarodnega nadzora nad to snovjo upravičena.
The Expert Committee recognises that MDBD-CHMICA has similar abuse to and similar ill-effects to those of substances in Schedule II of the Convention on Psychotropic Substances.
Zato SZO priporoča, da se MDMB-CHMICA uvrsti v Tabelo II Konvencije o psihotropnih substancah.
The Expert Committee considers that there is sufficient evidence that MDMB-CHMICA is being or is likely to be abused, and therefore constitutes a public health and social problem that warrants placing the substance under international control.
Po poročilu o oceni tveganja Evropskega centra za spremljanje drog in zasvojenosti z drogami, pripravljenem v skladu z določbami člena 6(2), (3) in (4) Sklepa 2005/387/PNZ ter predloženem Komisiji in Svetu 28. julija 2016, zaradi velike jakosti MDMB-CHMICA in izredno spremenljivih količin te spojine v „zakonitih drogah“ obstaja veliko tveganje za akutno strupenost.
Thus, the WHO recommends that MDMB-CHMICA be placed in Schedule II under the Convention on Psychotropic Substances.
Osem držav članic je poročalo o skupaj 28 smrtnih primerih in 25 akutnih zastrupitvah, povezanih z MDMB-CHMICA.
According to the risk assessment report of the European Monitoring Centre for Drugs and Drug Addiction, which was conducted under Article 6(2), (3) and (4) of Decision 2005/387/JHA and submitted on 28 July 2016 to the Commission and to the Council, the high potency of MDMB-CHMICA and the highly variable amounts of the compound in ‘legal high’ products constitute a high risk of acute toxicity.
Zato je Komisija 31. avgusta 2016 sprejela predlog za uvedbo nadzornih ukrepov na ravni EU za MDMB-CHMICA.
Eight Member States have reported a total of 28 deaths and 25 acute intoxications associated with MDMB-CHMICA.
Zato bi morale države članice zavzeti stališče, da se MDMB-CHMICA doda v Tabelo II Konvencije o psihotropnih substancah.
The Commission therefore adopted on 31 August 2016 a proposal to subject MDMB-CHMICA to Union-wide control measures.
Glede na oceno strokovnega odbora je stopnja tveganja za javno zdravje in družbo, povezana z zlorabo 5F-APINACA ali 5F-AKB-48 (N-(adamantan-1-il)-1-(5-fluoropentil)-1H-indazol-3-karboksamid), precejšnja.
Therefore, the Member States should take the position to add MDMB-CHMICA to Schedule II of the Convention on Psychotropic Substances.
Evidenc o njegovi terapevtski uporabi ni.
According to the Expert Committee, the degree of risk to public health and society associated with the abuse of 5F-APINACA or 5F-AKB-48 (N-(adamantan-1-yl)-1-(5-fluoropentyl)-1H-indazole-3-carboxamide) is substantial.
Strokovni odbor ugotavlja, da je 5F-APINACA mogoče podobno zlorabiti in da lahko ima podobne škodljive učinke kot snovi iz Tabele II Konvencije o psihotropnih substancah.
It has no recorded therapeutic use.
Ker po mnenju strokovnega odbora o zlorabi ali verjetnosti zlorabe 5F-APINACA obstaja dovolj dokazov in zato predstavlja problem javnega zdravja in družbeni problem, je uvedba mednarodnega nadzora nad to snovjo upravičena.
The Expert Committee recognises that 5F-APINACA has similar abuse potential to and similar ill-effects to those of substances in Schedule II of the Convention on Psychotropic Substances.
Zato SZO priporoča, da se 5F-APINACA uvrsti v Tabelo II Konvencije o psihotropnih substancah.
The Expert Committee considers that there is sufficient evidence that 5F-APINACA is being or is likely to be abused, and therefore constitutes a public health and social problem that warrants placing the substance under international control.
5F-APINACA spremlja Evropski center za spremljanje drog in zasvojenosti z drogami kot novo psihoaktivno snov pod pogoji Sklepa 2005/387/PNZ.
Thus, the WHO recommends that 5F-APINACA be placed in Schedule II under the Convention on Psychotropic Substances.
5F-APINACA je bil odkrit v 23 državah članicah.
5F-APINACA is monitored by the European Monitoring Centre for Drugs and Drug Addiction as a new psychoactive substance under the terms of Decision 2005/387/JHA.
Zato bi morale države članice zavzeti stališče, da se 5F-APINACA doda v Tabelo II Konvencije o psihotropnih substancah.
5F-APINACA has been detected in 23 Member States.
Glede na oceno strokovnega odbora je stopnja tveganja za javno zdravje in družbo, povezana z zlorabo XLR-11 [1-(5-fluoropentil)-1H-indol-3-il](2,2,3,3-tetrametilciklopropil)metanon, precejšnja.
Therefore, the Member States should take the position to add 5F-APINACA to Schedule II of the Convention on Psychotropic Substances.
Evidenc o terapevtski uporabi XLR-11 ni.
According to the Expert Committee, the degree of risk to public health and society associated with the abuse of XLR-11 [1-(5-fluoropentyl)-1H-indol-3-yl](2,2,3,3-tetramethylcyclopropyl)methanone is substantial.
Strokovni odbor ugotavlja, da je mogoče XLR-11 podobno zlorabiti in da lahko ima podobne škodljive učinke kot snovi iz Tabele II Konvencije o psihotropnih substancah, kot sta JWH-018 in AM-2201.
XLR-11 has no recorded therapeutic use.
Ker po mnenju strokovnega odbora o zlorabi ali verjetnosti zlorabe XLR-11 obstaja dovolj dokazov in zato predstavlja problem javnega zdravja in družbeni problem, je uvedba mednarodnega nadzora nad to snovjo upravičena.
The Expert Committee recognises that XLR-11 has similar abuse potential to and similar ill-effects to those of substances in Schedule II of the Convention on Psychotropic Substances such as JWH-018 and AM-2201.
Zato SZO priporoča, da se XLR-11 uvrsti v Tabelo II Konvencije o psihotropnih substancah.
The Expert Committee considers that there is sufficient evidence that XLR-11 is being or is likely to be abused, and therefore constitutes a public health and social problem that warrants placing the substance under international control.
XLR-11 spremlja Evropski center za spremljanje drog in zasvojenosti z drogami kot novo psihoaktivno snov pod pogoji Sklepa 2005/387/PNZ.
Thus, the WHO recommends that XLR-11 be placed in Schedule II under the Convention on Psychotropic Substances.
XLR-11 je bil odkrit v 17 državah članicah Unije.
XLR-11 is monitored by the European Monitoring Centre for Drugs and Drug Addiction as a new psychoactive substance under the terms of Decision 2005/387/JHA.
Povezan je z manjšim številom resnih neželenih dogodkov, med drugim z najmanj enim odkritim smrtnim primerom, in v okviru sistema zgodnjega opozarjanja na nevarnost je bilo objavljeno opozorilo o nevarnosti, ki jo pomeni za javno zdravje.
XLR-11 has been detected in 17 Member States.
Zato bi morale države članice zavzeti stališče, da se XLR-11 doda v Tabelo II Konvencije o psihotropnih substancah.
It has been associated with small number of serious adverse events, including at least one death in which it was detected, and has been the subject of a public-health-related alert issued to the Union Early Warning System.
Okvirni sklep 2004/757/PNZ in Sklep Sveta 2005/387/PNZ sta za Dansko zavezujoča, zato sodeluje pri sprejetju in uporabi tega sklepa.
Therefore, the Member States should take the position to add XLR-11 to Schedule II of the Convention on Psychotropic Substances.
Okvirni sklep 2004/757/PNZ in Sklep 2005/387/PNZ sta za Irsko zavezujoča, zato sodeluje pri sprejetju in uporabi tega sklepa.
Denmark is bound by Framework Decision 2004/757/JHA and Decision 2005/387/JHA and is therefore taking part in the adoption and application of this Decision.
Okvirni sklep 2004/757/PNZ in Sklep 2005/387/PNZ za Združeno kraljestvo nista zavezujoča, zato ne sodeluje pri sprejetju tega sklepa, ki zanj ni zavezujoč in se v njem ne uporablja –
Ireland is bound by Framework Decision 2004/757/JHA and Decision 2005/387/JHA and is therefore taking part in the adoption and application of this Decision.
SPREJEL NASLEDNJI SKLEP:
The United Kingdom is not bound by Framework Decision 2004/757/JHA and Decision 2005/387/JHA and is therefore not taking part in the adoption of this Decision, and is not bound by it or subject to its application,
Člen 1
HAS ADOPTED THIS DECISION:
Stališče, ki ga v imenu Evropske unije zavzamejo države članice v Komisiji za droge 13. do 17. marca 2017, ko naj bi navedeni organ na šestdesetem zasedanju sprejel sklepe o vključitvi dodatnih snovi v tabele Enotne konvencije Združenih narodov o mamilih iz leta 1961, kakor je bila spremenjena s Protokolom iz leta 1972, in Konvencije Združenih narodov o psihotropnih substancah iz leta 1971, je v skladu s Prilogo k temu sklepu.
Article 1
Stališče izrazijo države članice, ki so članice Komisije za droge, pri čemer nastopajo skupaj v interesu Unije.
The position to be adopted on the Union's behalf by the Member States in the Commission on Narcotic Drugs on 13 to 17 March 2017, when that body is called upon to adopt decisions on the addition of substances to the Schedules of the United Nations Single Convention on Narcotic Drugs of 1961 as amended by the 1972 Protocol and the United Nations Convention on Psychotropic Substances of 1971 at its 60th session, shall be in accordance with the Annex to this Decision.
Člen 2
The position shall be expressed by the Member States that are members of the Commission on Narcotic Drugs, acting jointly in the interest of the Union.
Ta sklep je naslovljen na države članice v skladu s Pogodbama.
This Decision is addressed to the Member States in accordance with the Treaties.
Za Svet
For the Council
Okvirni sklep Sveta 2004/757/PNZ z dne 25. oktobra 2004 o opredelitvi minimalnih določb glede elementov kaznivih dejanj in kazni na področju nedovoljenega prometa s prepovedanimi drogami (UL L 335, 11.11.2004, str. 8).
The President
Sklep Sveta 2005/387/PNZ z dne 10. maja 2005 o izmenjavi podatkov, oceni tveganja in nadzoru nad novimi psihoaktivnimi snovmi (UL L 127, 20.5.2005, str. 32).
Council Framework Decision 2004/757/JHA of 25 October 2004 laying down minimum provisions on the constituent elements of criminal acts and penalties in the field of illicit drug trafficking (OJ L 335, 11.11.2004, p. 8).
PRILOGA
Council Decision 2005/387/JHA of 10 May 2005 on the information exchange, risk-assessment and control of new psychoactive substances (OJ L 127, 20.5.2005, p. 32).
Stališče, ki ga zavzamejo države članice, ki so članice Komisije za droge, pri čemer nastopajo skupaj v interesu Unije, na šestdesetem zasedanju Komisije za droge, ki bo 13. do 17. marca 2017 v zvezi s spremembami področja nadzora snovi:
ANNEX
U-47700 je treba vključiti v Tabelo I Enotne konvencije o mamilih iz leta 1961, kakor je bila spremenjena s Protokolom iz leta 1972.
Position to be taken by the Member States which are members of the Commission on Narcotic Drugs acting jointly in the interest of the Union during the 60th session of the Commission on Narcotic Drugs on 13 to 17 March 2017 regarding changes in the scope of control of substances:
Butirfentanil je treba vključiti v Tabelo I Enotne konvencije o mamilih iz leta 1961, kakor je bila spremenjena s Protokolom iz leta 1972.
U-47700 is to be included in Schedule I of the Single Convention of Narcotic Drugs of 1961 as amended by the 1972 Protocol.
EC (4-metiletkatinon) je treba vključiti v Tabelo II Konvencije o psihotropnih substancah iz leta 1971.
Butyrfentanyl is to be included in Schedule I of the Single Convention on Narcotic Drugs of 1961 as amended by the 1972 Protocol.
Etilon je treba vključiti v Tabelo II Konvencije o psihotropnih substancah iz leta 1971.
EC (4-methylethcathinone) is to be included in Schedule II of 1971 Convention on Psychotropic Substances.
Pentedron (α-metilaminovalerofenon) je treba vključiti v Tabelo II Konvencije o psihotropnih substancah iz leta 1971.
Ethylone is to be included in Schedule II of the Convention on Psychotropic Substances of 1971.
Etilfenidat (EPH) je treba vključiti v Tabelo II Konvencije o psihotropnih substancah iz leta 1971.
Pentedrone (α-methylaminovalerophenone) is to be included in Schedule II of the Convention on Psychotropic Substances of 1971.
MPA (metiopropamin) je treba vključiti v Tabelo II Konvencije o psihotropnih substancah iz leta 1971.
Ethylphenidate (EPH) is to be included in Schedule II of the Convention on Psychotropic Substances of 1971.
MDMB-CHMICA je treba vključiti v Tabelo II Konvencije o psihotropnih substancah iz leta 1971.
MPA (methiopropamine) is to be included in Schedule II of the Convention on Psychotropic Substances of 1971.
5F-APINACA (5F-AKB48) je treba vključiti v Tabelo II Konvencije o psihotropnih substancah iz leta 1971.
MDMB-CHMICA is to be included in Schedule II of the Convention on Psychotropic Substances of 1971.
XLR-11 je treba vključiti v Tabelo II Konvencije o psihotropnih substancah iz leta 1971.
5F-APINACA (5F-AKB48) is to be included in Schedule II of the Convention on Psychotropic Substances of 1971.
Strokovni odbor ugotavlja, da se pentedron podobno zlorablja in ima podobne škodljive učinke kot snovi iz Tabele II Konvencije o psihotropnih substancah.
XLR-11 is to be included in Schedule II of the Convention on Psychotropic Substances of 1971.
Ker po mnenju strokovnega odbora o zlorabi ali verjetnosti zlorabe pentedrona obstaja dovolj dokazov in zato predstavlja problem javnega zdravja in družbeni problem, je uvedba mednarodnega nadzora nad to snovjo upravičena.
Commission Implementing Decision (EU) 2017/450
Izvedbeni sklep Komisije (EU) 2017/450
authorising the placing on the market of lactitol as a novel food ingredient under Regulation (EC) No 258/97 of the European Parliament and of the Council
o odobritvi dajanja na trg laktitola kot nove živilske sestavine v skladu z Uredbo (ES) št. 258/97 Evropskega parlamenta in Sveta
(notified under document C(2017) 1576)
(notificirano pod dokumentarno številko C(2017) 1576)
On 16 March 2015, the company DuPont Nutrition Biosciences ApS made a request to the competent authorities of Denmark to place lactitol on the Union market as a novel food ingredient within the meaning of point (c) of Article 1(2) of Regulation (EC) No 258/97.
Družba DuPont Nutrition Biosciences ApS je 16. marca 2015 pri pristojnih organih Danske vložila zahtevek za dajanje na trg Unije laktitola kot nove živilske sestavine v smislu točke (c) člena 1(2) Uredbe (ES) št. 258/97.
In its request, the company proposes lactitol to be used in the same food categories and in the same use levels that are currently being used, when lactitol is added as a food additive under Annex II to Regulation (EC) No 1333/2008 of the European Parliament and of the Council [2].
Podjetje v svojem zahtevku predlaga laktitol za uporabo v istih kategorijah živil in na istih ravneh uporabe, kot se trenutno uporabljajo, če se laktitol doda kot aditiv za živila iz Priloge II k Uredbi (ES) št. 1333/2008 Evropskega parlamenta in Sveta [2].
On 1 July 2015, the competent food assessment body of Denmark issued its initial assessment report.
Danski pristojni organ za presojo živil je 1. julija 2015 izdal poročilo o začetni presoji.
In that report it came to the conclusion that lactitol under the conditions of use proposed by the applicant meets the criteria for novel food ingredients set out in Article 3(1) of Regulation (EC) No 258/97.
V navedenem poročilu je ugotovil, da laktitol pod pogoji uporabe, ki jih je predlagal prosilec, izpolnjuje merila za nove živilske sestavine iz člena 3(1) Uredbe (ES) št. 258/97.
On 13 July 2015, the Commission forwarded the initial assessment report to the other Member States.
Komisija je 13. julija 2015 poročilo o začetni presoji poslala drugim državam članicam.
Some Member States made comments within the 60-day period laid down in the first subparagraph of Article 6(4) of Regulation (EC) No 258/97.
Nekatere države članice so v 60-dnevnem roku, ki je določen v prvem pododstavku člena 6(4) Uredbe (ES) št. 258/97, podale pripombe.
Concerns were raised regarding the excess of lactitol intake and the possibility of misleading the consumer as the same uses and use levels are already authorised for lactitol as a food additive.
Pomisleki so bili izraženi glede prekomernega vnosa laktitola in morebitnega zavajanja potrošnikov, saj so enake uporabe in ravni uporabe že dovoljene za laktitol kot aditiv za živila.